The Top Line
από Fierce Life Sciences
Τελευταίο επεισόδιο
Digital Twins: Advancing Clinical Evidence Strategy (Sponsored)
Digital Twins: Advancing Clinical Evidence Strategy (Sponsored)
Σχετικά με αυτό το podcast
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.
Επεισόδια
Τα νεότερα 20 από 100 επεισόδια
- Digital Twins: Advancing Clinical Evidence Strategy (Sponsored) · 20 λεπ.Patient digital twins give life sciences teams a framework for evaluating how an individual patient’s health trajectory could change under different treatments or scenarios. In…
- When drug development gets personal · 28 λεπ.For nearly three decades, Jigar Raythatha has helped build biotech companies and bring new medicines to patients. But in 2023, the Third Rock Ventures partner found himself on…
- How AI turns field conversations into actionable insights (Sponsored) · 16 λεπ.Life science field teams are a major source of customer insight, but growing complexity, limited HCP access and expanding omnichannel demands can make it difficult to turn every…
- Use Kidney Genetics to Strengthen Clinical Trial Design (Sponsored) · 15 λεπ.Broad chronic kidney disease labels can obscure distinct biology, complicating patient selection, progression assumptions and treatment-signal interpretation. In this sponsored…
- GSK's double FDA win, Roche's $15B deal and the rise of point-of-care marketing · 15 λεπ.In this week's episode of "The Top Line," we're covering a pair of FDA approvals for GSK, an antibody-drug conjugate pact worth up to $15 billion and the growing role of…
- Inside Teva's Weltruza launch and Novo's GLP-1 strategy · 25 λεπ.In this week's episode of "The Top Line," we're looking at two companies building on recent successes and pursuing new opportunities in the pharmaceutical industry. From Teva's…
- The Next Chapter for AI in Clinical Trials [Sponsored] · 33 λεπ.Clinical AI is moving from systems that predict and summarize toward agents that can help execute parts of a workflow. In this sponsored episode of The Top Line, Will Hurth…
- How AI could improve clinical trial decision-making (Sponsored) · 23 λεπ.What if clinical development teams could evaluate potential trial outcomes before a study reaches patients? In this sponsored episode of The Top Line, host Irena Luo speaks with…
- How we picked the Fierce 15 · 23 λεπ.What does it mean to be a Fierce 15 biotech in 2026? With this year’s list unveiled, the Fierce Biotech team gets together to discuss what the winners tell us about the state of…
- Locking in on pharma’s consumerization trend · 19 λεπ.With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. Now, the CEO of a buzzy pattern-hair-loss biotech is eyeing…
- Fierce Pharma Week: A look at the biggest trends, campaigns and conversations · 25 λεπ.Fierce Pharma Week brought thousands of people to Philadelphia for four days of conversations about pharma marketing, commercialization, medical affairs and communications. In…
- Inside the growing world of biopharma prediction markets · 24 λεπ.Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. But they also create a new set of risks for an industry…
- Clinical trials reach a new automation inflection point (Sponsored) · 17 λεπ.Clinical development organizations are facing mounting pressure to do more with increasingly complex protocols, larger data sets and tighter timelines. While automation has…
- The future of RAS inhibitors · 29 λεπ.Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs…
- The people who stayed with the problem · 25 λεπ.The 2026 Fierce 50 includes people and organizations working on very different problems across biopharma and healthcare, from designing new proteins and developing cancer…
- Why Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored) · 13 λεπ.The promise of precision medicine depends on more than scientific innovation. It also depends on whether eligible patients can be identified, tested and connected to the most…
- MrBeast, Snapchat, AI and more: Pharma marketing’s pulse check · 21 λεπ.As Fierce Pharma Week approaches, the Fierce Pharma Marketing team is taking stock of some of the biggest trends reshaping how drugmakers and healthcare agencies reach audiences…
- What did we learn from Big Pharma’s Q2 results? · 33 λεπ.Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no different. From the rollout of AI to the oral GLP-1…
- How consumerization is reshaping pharma marketing (Sponsored) · 17 λεπ.Consumerization is changing how patients engage with healthcare, and pharma companies may need to rethink how they approach awareness, diagnosis and commercialization. In this…
- A genomics library for the AI era · 23 λεπ.Having spent 14 years building out its capacity, Regeneron Genetics Center—the genomic research branch of the Tarrytown, New York-based pharma—is a pro when it comes to the sort…
